Table 1 PK parameters of IBI319 after a single intravenous injection of 0.1, 1, or 10 mg/kg into cynomolgus monkeys (mean ± SD, n = 6).

From: Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity

Dose (mg/kg)

t1/2 (h)

AUC0-t (h·μg/mL)

AUC0-∞ (h·μg/mL)

Vss (mL/kg)

CL (mL/h/kg)

MRT0-t (h)

Cmax (μg/mL)

Tmax (h)

0.1

25.50 ± 9.65

62.70 ± 25.60

71.10 ± 30.10

47.30 ± 6.38

1.62 ± 0.65

22.60 ± 7.54

2.65 ± 0.40

0.083 ± 0.00

1

50.50 ± 10.40

1420.00 ± 602.00

1510.00 ± 554.00

58.20 ± 22.00

0.74 ± 0.27

62.90 ± 11.30

27.80 ± 6.46

0.083 ± 0.00

10

63.40 ± 40.90

13,900.00 ± 2850.00

15,100.00 ± 2970.00

64.10 ± 23.70

0.69 ± 0.13

73.10 ± 8.05

240.00 ± 47.90

0.40 ± 0.78

  1. t1/2 effective half-time, AUC0-t area under the serum drug concentration-time curve up from time zero to the last measurable concentration, AUC0-∞ area under the serum concentration-time curve from time zero to infinity, which was calculated from the terminal phase data harvested; Vss apparent volume of distribution in the steady state, CL total body clearance following vascular administration of the drug, MRT0-t mean reaction time from time zero to the last measurable concentration, Cmax maximum drug concentration observed in the serum, Tmax time of the first occurrence of Cmax.
Back to article page